Male Contraceptive Initiative: Innovation Awards / Development Awards

Male Contraceptive Initiative (MCI) is a US-based 501(c)3 nonprofit funder and advocate for safe, effective, and reversible contraceptive solutions for sperm-producing individuals.

Nearly half of all pregnancies worldwide are unintended. Furthermore, male contraceptives are limited to condoms and vasectomy, which do not provide adequate variety in characteristics to meet the needs of all users. This Request for Applications (RFA) contains two separate funding tracks in order to support research ranging from target identification studies to late preclinical development. The emphasis for this funding opportunity
is encouraging the development of safe, effective, and reversible male contraceptives that are distinct from existing methods and have profiles that appeal to a broad base of users.

The David Sokal Innovation Awards provide a maximum award of $200,000 over the project period and are intended to spur novel contraceptive research pathways. Sokal Awards are designed to enable projects in the early stages of contraceptive discovery and development with demonstrated Proof of Concept to de-risk and move closer towards or into active contraceptive development. Sokal Award applications may focus on, but are not limited to, identification of contraceptive targets, inquiries into biological mechanisms of validated contraceptive targets, discovery of agents with potential contraceptive application, early development of contraceptives for men, as well as tools, techniques, and delivery devices that expand contraceptive research capabilities.

Development Awards provide a maximum award of $400,000 over the project period and are intended to support projects in active contraceptive development with activities up to and through regulatory approval for first-in human studies. This funding category requires both Proof of Concept and demonstrated progress towards a specific contraceptive compound or device. Demonstrated progress may include lead compounds with suitable pharmaceutical properties for downstream development, in vivo or other pre-clinical data of relevant compounds or devices, or a clearly articulated pathway towards regulatory approval. Development Award applications may focus on, but are not limited to, refinement of specific compounds to improve selectivity, potency and drug-like properties, refinement and testing of device modifications, in vitro and in vivo preclinical studies such as pharmacokinetics / pharmacodynamics (PK/PD), absorption, distribution, metabolism, and excretion (ADME), toxicology studies, and other evaluations required to progress into clinical stages of development.

This application is open to academic institutions, for-profit organizations, and other entities, foreign and domestic. Any individual(s) with the skills, knowledge, and internal or external resources necessary to carry out the proposed research as a Principal Investigator (PI) is invited to work with their organization to develop an application for support.